

# We are IntechOpen, the world's leading publisher of Open Access books Built by scientists, for scientists

6,900

Open access books available

186,000

International authors and editors

200M

Downloads

Our authors are among the

154

Countries delivered to

TOP 1%

most cited scientists

12.2%

Contributors from top 500 universities



WEB OF SCIENCE™

Selection of our books indexed in the Book Citation Index  
in Web of Science™ Core Collection (BKCI)

Interested in publishing with us?  
Contact [book.department@intechopen.com](mailto:book.department@intechopen.com)

Numbers displayed above are based on latest data collected.  
For more information visit [www.intechopen.com](http://www.intechopen.com)



# Predictors of Resistance Hypertension and Achievement of Target Blood Pressure Levels in Patients with Resistant Hypertension

*Yuriy Mykolayovych Sirenko, Oksana Leonidivna Rekovets and Olena Oleksandrivna Torbas*

## Abstract

Uncontrolled arterial pressure is associated with a fourfold increase in the risk of developing cardiovascular events compared to patients with hypertension who have reached the target blood pressure level. The aim of this study is to evaluate the characteristics of patients with resistant arterial hypertension undergoing inpatient treatment at the Department of Symptomatic Hypertension and assess the prevalence of true resistant hypertension in a cohort of patients who take 3 and more antihypertensive agents, the clinical predictors of resistant hypertension. The study included 1146 patients with resistant AH who received 3 or more antihypertensive drugs with the level of office blood pressure at admission  $\geq 140/90$  mm Hg. Patients were followed by the next examinations: body height and body measurements, office blood pressure, echocardiography, sleep apnea determination, blood biochemical analysis, determination of levels of TTH, T3, T4, blood renin, blood aldosterone, metanephrine urine, and cortisol. Our data showed that 31% of patients who received 3 or more antihypertensive drugs had true resistant hypertension. Fixed combinations were taken by 71.9% of patients. We have found which factors were significantly associated with the treatment regimen with  $\geq 3$  or 4 drugs. Also we have demonstrated predictors for blood pressure reduction.

**Keywords:** resistant hypertension, pharmacology, predictors of resistance hypertension, target blood pressure, anti-hypertensive drugs

## 1. Background

The prevalence of resistant hypertension is very different according to different studies. In an analysis of National Health and Nutrition Examination Survey (NHANES) participants being treated for hypertension, only 53% were controlled to 140/90 mm Hg [1]. In Framingham Heart Study participants, only 48% of treated patients were controlled to 140/90 mm Hg, and less than 40% of elderly participants (75 years of age) were at a goal blood pressure [2]. Among higher-risk populations and, in particular, with application of the lower goal blood

pressures recommended in the Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure (JNC 7) for patients with diabetes mellitus or chronic kidney disease (CKD), the proportion of uncontrolled patients is even higher. Of NHANES participants with chronic kidney disease, only 37% were controlled to 130/80 mm Hg<sup>3</sup>, and only 25% of participants with diabetes were controlled to 130/85 mm Hg [1, 3].

An estimated 10–30% of hypertensive patients are resistant to treatment defined as uncontrolled blood pressure (BP) with the use of  $\geq 3$  medications, including a diuretic [4–10]. A large number of studies have demonstrated that patients with resistant hypertension compared with patients with controlled hypertension have significantly a higher rate of target organ damage; increased cardiovascular risk, including coronary heart disease, chronic kidney disease, congestive heart failure, and stroke; and a significantly poorer prognosis than those of nonresistant hypertensive patients [3, 11].

Poor medical adherence, poor blood pressure measuring technique, and white-coat effect are relevant challenges to figuring out the real burden of resistant hypertension [11].

Previous studies have shown that obesity is associated with resistant AH [12]. In addition, other studies have shown that diabetes is associated with a resistant hypertension [13, 14]. Studies show that resistant AH is associated with an increase in age, female gender, Negroid race, the presence of diabetes mellitus, obesity, chronic kidney disease, and left ventricular hypertrophy [1, 10, 15–19]. For early detection of resistant AH, aggressive therapy can reduce both cardiovascular morbidity and mortality. However, the exact prevalence of resistant AH is not known precisely because of its variety of definitions and diversity of study sites [20, 21].

Increased blood pressure is one of the most important risk factors for stroke [4, 6, 22], and uncontrolled hypertension increases this risk [1, 23]. The prevalence of hypertension in Asian countries is almost the same as in most developed countries; many Asian patients have uncontrolled hypertension compared with developed countries [24]. For example, in developed countries, blood pressure monitoring is about 52–60%, but in Malaysia, for example, this figure is 26% [2, 11, 24–26]. In Ukraine, blood pressure control in the urban population is 14% and in rural populations 8% [27, 28].

In the current study, we have assessed the prevalence of true resistant hypertension in a cohort of patients who take 3 and more antihypertensive agents, the clinical predictors of resistant hypertension.

## **2. Material and methods**

The study included 1146 patients with resistant AH who received 3 or more antihypertensive drugs who were hospitalized in 2011–2015 at the Department of Symptomatic Hypertension at the Institute of Cardiology of Ukraine, Kyiv. The level of office blood pressure when admitted to the office when receiving 3 or more AH drugs was  $\geq 140/90$  mm Hg. The average systolic blood pressure (SBP)/diastolic blood pressure (DBP) was  $174,60 \pm 0,64/100,50 \pm 0,38$  mm Hg.

Inclusion criteria. The inclusion criteria are as follows: (1) men and women aged between 18 and 80 years old and (2) patients treated with 3 and more antihypertensive drugs. The diagnosis of RH was made after treatment with three antihypertensive drug classes at maximum tolerated doses for at least 6 months. The study did not include patients with acute myocardial infarction or cerebrovascular accidents less than 3 months, acute renal failure, decompensated liver disease (level of AST, ALT above 3 times upper limit of normal), pregnancy, or lactation.

Anthropometric measurements. Weight and height, measured by anthropometric scales, will be used to calculate the body mass index (BMI) using the formula

Parameters	Value
Men, n (%)	423 (36,91%)
Women, n (%)	723 (63,09%)
Height, m	1,7 ± 0,01
Weight, kg	87,7 ± 0,61
Age, years	57,9 ± 0,37
BMI, kg/m <sup>2</sup>	31,0 ± 0,19
Office SBP mm Hg at hospitalization	174,6 ± 0,64
Office DBP mm Hg at hospitalization	100,5 ± 0,38
Office SBP mm Hg on discharge from hospital	131,3 ± 0,40
Office DBP mm Hg on discharge from hospital	80,1 ± 0,65
Index of apnea-hypopnea, events /h, (n = 75)	18,8 ± 2,11
AO, sm	3,4 ± 0,05
LA, sm	3,9 ± 0,06
Left ventricle end-systolic dimension, sm	3,5 ± 0,08
Left ventricle end-diastolic dimension, sm	5,5 ± 0,13
Left ventricle end-systolic volume, mL	48,3 ± 0,68
Left ventricle end-diastolic volume, mL	126,3 ± 1,17
Inter ventricular septum thickness, sm	1,2 ± 0,01
Left ventricle posterior wall thickness, sm	1,1 ± 0,01
EF, %	60,6 ± 0,23
Left ventricular mass index, g/m <sup>2</sup>	138,2 ± 1,43
K, mmol/l	5,1 ± 0,49
Na, mmol/l	144,0 ± 0,30
Bilirubin, µmol/l	14,1 ± 0,21
Creatinine, µmol/l	87,2 ± 0,58
CKD-EPI, ml/min/1.73 m <sup>2</sup>	82,7 ± 0,96
ALT, U/l	47,5 ± 3,39
AST, U/l	27,1 ± 0,71
Fasting glucose, mmol/l	6,0 ± 0,08
Uric acid, mmol/l (n = 850)	336,2 ± 3,62
Triiodothyronine (T3), microU/l (n = 94)	4,6 ± 1,16
Thyroxin (T4), microU/l (n = 111)	3,2 ± 0,67
Thyroid hormone (TTH), microU/l (n = 231)	2,2 ± 0,15
Metanephrine urine, microG/24 h (n = 95)	124,5 ± 7,10
Renin, ng/l (n = 89)	155,2 ± 79,73
Aldosterone, ng/l (n = 118)	29,4 ± 2,90
Aldosterone-renin ratio, c.u. (n = 75)	3,3 ± 0,68
Cortisol, ng/l (n = 21)	108,0 ± 30,73
Total cholesterol, mmol/l	5,5 ± 0,04
Triglycerides, mmol/l	1,6 ± 0,04
HDL cholesterol, mmol/l	1,3 ± 0,02
LDL cholesterol, mmol/l	3,3 ± 0,07
VLDL cholesterol, mmol/l	0,7 ± 0,02
IA (index of atherogenicity), c.u.	3,3 ± 0,07

**Table 1.**  
*Clinical and demographic characteristics of the examined patients (n = 1146).*

BMI = weight (kg)/height squared ( $\text{m}^2$ ). BMIs of 18.5–26.9  $\text{kg}/\text{m}^2$  are considered eutrophic values, while individuals with BMIs of 27.0–29.9  $\text{kg}/\text{m}^2$  are overweight and  $\geq 30$   $\text{kg}/\text{m}^2$  are obese.

All patients will undergo electrocardiography, echocardiography, and office-measured SBP and DBP; an oscillometric device will be used to calculate the average of the three measurements. Biochemical and imaging tests. Blood samples will be drawn from all patients at the first visits after fasting for 12 h to measure serum total cholesterol, high-density lipoprotein cholesterol (HDLc), low-density lipoprotein cholesterol (LDLc), very low-density lipoprotein cholesterol (VLDLc), triglycerides (TG), glucose, creatinine, sodium, and potassium; blood renin, aldosterone and aldosterone/renin ratio, metanephrines in urine, blood cortisol level, T3, T4, and TTH were determined in some patients. CKD-EPI was calculated. If needed, CT with intravenous contrast renal arteries and adrenal glands (for exclusion, secondary hypertension) and sleep apnea determination were performed on some patients (**Table 1**).

Statistical processing of the results was performed on a personal computer after creating databases in Microsoft Excel systems. The mean of the patients examined was determined using the analysis package in Microsoft Excel. All other statistical calculations were performed using SPSS 21.0. ANOVA to calculate the following parameters: the arithmetic mean value,  $M$ ; the SD from the arithmetic mean value of  $m$ ; and coefficient of reliability,  $p$ . The difference was considered reliable at a value of  $p < 0.05$ . The reliability of the difference between the groups was determined by the independent t-test for the mean. Correlation analysis was performed after determining the character of the distribution for Spearman.

### 3. Results

We examined 1146 patients who received 3 or more antihypertensive drugs. The mean age was  $57,9 \pm 0,37$  years. The average body weight is  $87,7 \pm 0,61$  kg. The average body mass index was  $31,0 \pm 0,19$   $\text{kg}/\text{m}^2$ . Average baseline office SBP and DBP were  $174,6 \pm 0,64$  and  $100,5 \pm 0,38$  mm Hg accordingly.

Most of the patients received 3 antihypertensive drugs: 51.4%. 48.6% of the patients take four to six drugs. Most of them take four drugs, 37.1%, 9.1% five drugs, and 2.4% six drugs.

The frequency of appointment of different classes of antihypertensive agents in the examined patients is presented in **Table 2**. In the structure of the appointments of antihypertensive drugs (AHD), ACE inhibitors were prescribed more often, 65.5%; calcium antagonists, 69.9%; and diuretics (loop, thiazide, and thiazide like), 91.8%. Beta-blockers were taken by 75.6% of patients and blockers to AT II receptor, 33.5%. Aldosterone receptor blockers were taken by 12.8% of patients and central activity drugs, 18.6%. Statins were taken by 63.8% of patients. Among those receiving combined therapy, most (71.9%) take fixed combinations. Attention was given to the low frequency of aldosterone receptor blockers received (12.8%), which was due to the fact that the study was conducted predominantly until the year 2015, when there was scientific evidence of the need for their use as the fourth drug.

For further analysis, we divided our patients according to the amount of drugs that they received. Although 3 or more antihypertensive drugs are used in the determination of resistant hypertension, we divided our patients into two groups: the first, those who took 3 drugs, and the second, those who took 4 or more drugs. A comparison of demographic characteristics and blood pressure levels in these groups is presented in **Table 3**.



Antihypertensive class	%
Angiotensin-converting enzyme inhibitors	65,5
Angiotensinogen receptor blockers	33,5
Calcium channel blockers	69,9
Diuretics (thiazide, loops, thiazide like)	91,8
β-Blockers	75,6
Mineralocorticoid receptor antagonists	12,8
Central-acting agonists	18,6
α-Blockers	2,6
Fixed combination	71,9
Acetylsalicylic acid	68,3
Statins	63,8

**Table 2.**  
*Frequency of appointment of antihypertensive drugs of different classes among patients with resistant arterial hypertension (n = 1146).*

Parameters	Value		P
	3 drugs (n = 591)	≥4 drugs (n = 555)	
Men/women, n (%)	231 (39,0)/360 (60,8)	192 (34,6)/363 (65,4)	NS
Age, years	57,2 ± 0,54	58,7 ± 0,48	NS
Height, m	1,7 ± 0,01	1,7 ± 0,01	NS
Weight, kg	85,9 ± 0,85	89,3 ± 0,86	0,004
BMI, kg/m <sup>2</sup>	30,2 ± 0,26	31,6 ± 0,27	<0,001
Office SBP mm Hg at hospitalization	170,4 ± 0,79	179,0 ± 1,00	<0,001
Office DBP mm Hg at hospitalization	98,4 ± 0,48	102,6 ± 0,58	<0,001
Office SBP mm Hg on discharge from hospital	129,3 ± 0,52	133,5 ± 0,59	<0,001
Office DBP mm Hg on discharge from hospital	78,5 ± 0,33	81,8 ± 1,29	0,013
Index of apnea-hypopnea, events/h*	18,7 ± 3,07	18,9 ± 2,90	NS

\*The somnography was performed in 31 patients in the first group and in 44 patients in the second group.

**Table 3.**  
*Characteristics of patients, depending on the number of prescribed antihypertensive drugs (n = 1146).*

As can be seen from the table, the groups did not differ by age and sex on average, but patients taking ≥4 drugs had significantly higher body mass and BMI than the group of patients taking 3 drugs. They also had significantly higher levels of office BP, both when they arrived in the hospital and on discharge. It should be noted that in both groups the value of the apnea-hypopnea index was high but did not differ from each other.

According to laboratory tests, patients taking ≥4 drugs had significantly higher blood glucose levels—(6.20 ± 0.09) mmol—than patients taking 3 drugs, (5.90 ± 0.14) mmol (p < 0.05), and a higher level of renin plasma ((218.30 ± 15.73) vs. (31.10 ± 5.91) ng/l, (p < 0.05)). Renin-aldosterone ratio was almost twice as high

(3.90 ± 0.95 vs. 2.20 ± 0.65 U/d), although it did not differ significantly between patient groups.

Analyzing the differences between patients in both groups in the main clinical states, we found that in patients receiving 4 or more drugs, significantly more obesity (45.6 vs. 34.0%), more often secondary hypertension (5.4 against 2.5%) due to stenosis of the renal arteries (1.6 vs. 0.2%), and hyperaldosteronism (2.3 vs. 0.2%) were observed; type II diabetes mellitus was more frequent (24.7 vs. 9, 5%); pathology of the thyroid gland (12.6 vs. 8.4%) due to hypothyroidism (4.1 vs. 1.5%) and chronic kidney disease were more common (5.0 vs. 1.5%); and chronic pyelonephritis (18.9 vs. 14.0%), ischemic heart disease (IHD) (47.0 vs. 37.2%) with angina pectoris III (7.7 vs. 3.4%), and heart failure (15.0 vs. 9.3%) were observed.

In analyzing the degree of decrease in blood pressure, we found that, in general, the reduction of office blood pressure among patients receiving 3 or more drugs was for SBP (43,47 ± 0,65) mm Hg and for DBP (20,33 ± 0.74) mm Hg, p < 0.001 for both values.

The analysis of the degree of reduction of blood pressure, depending on the amount of drugs, showed that DBP between patients taking 3 and 4 or more drugs did not differ significantly, 19.88 versus 20.81 mm Hg, respectively, and office SBP significantly lowered in patients taking 4 or more drugs at 45.78 mm Hg vs. group taking 3 drugs—41.3 mm Hg, p < 0.001.

Among all patients (n = 1146), 355 (31%) did not reach the target blood pressure level. Patients who did not achieve targeted SBP (31%) had significantly higher blood pressure when inpatient. They had a significantly higher blood cortisol

	SBP on discharge		DBP on discharge	
Age	β = −0,089	P < 0,001	β = −0,196	P < 0,001
Gender	β = 0,125	P < 0,001	β = 0,130	P < 0,001
Weight	β = 0,106	P = 0,004	β = 0,127	P < 0,001
BMI			β = −0,202	P = 0,010
Arterial hypertension	β = 0,205	P = 0,001	β = 0,117	P < 0,001
Arterial hypertension II	β = 0,108	P = 0,001	β = 0,133	P < 0,001
Arterial hypertension III	β = −0,259	P = 0,023	β = −0,106	P = 0,001
Secondary arterial hypertension	β = −0,096	P = 0,006	β = −0,114	P < 0,001
Vasorenal arterial hypertension	β = −0,082	P = 0,011	β = −0,101	P = 0,002
Hyperaldosteronism	β = −0,103	P = 0,022	β = −0,071	P = 0,027
Pituitary adenoma			β = −0,089	P = 0,006
Heart failure			β = 0,146	P < 0,001
Heart failure II	β = −0,079	P = 0,014	β = −0,103	P = 0,002
Adrenal pathology	β = −0,065	P = 0,043	β = −0,070	P = 0,029
T4	β = −0,230	P = 0,020	β = −0,219	P = 0,027
Interventricular septum thickness	β = 0,214	P = 0,027	β = 0,154	P < 0,001
HD cholesterol	β = −0,230	P = 0,001	β = −0,198	P = 0,003
Calcium channel blockers	β = −0,140	P < 0,001	β = −0,080	P = 0,013
Central-acting agonists	β = −0,214	P < 0,001	β = −0,137	P < 0,001
Mineralocorticoid receptor antagonists	β = −0,101	P = 0,002	β = −0,096	P = 0,005
Acetylsalicylic acid	β = 0,169	P < 0,001	β = 0,197	P < 0,001

**Table 4.**  
*Factors influencing the reduction of blood pressure on discharge from the hospital (n = 1146).*

level ( $155.0 \pm 44.0$  vs.  $35.9 \pm 20.8$  ng/l) and the highest left ventricular mass index ( $147.5 \pm 3.46$  vs.  $135.3 \pm 1.74$  g/m<sup>2</sup>), and obesity (42.9 vs. 37.5%), kidney abnormality (2.7 vs. 0.8%), obliterative lower extremity atherosclerosis (2.0 vs. 0.2%), structural alterations in the adrenal gland (3.0 vs. 1.2%), nephropathy (1.3 vs. 0.2%), and higher heart failure (HF in the 16.9 vs. 8.5%) were more common.

When we performed a regression analysis, we found that the decrease in office systolic and diastolic blood pressure depended on age, sex, and body weight. Thus, office SBP/DBP was worse in men; patients with a younger age; patients with greater body mass, with hypertension III degree, and with secondary hypertension, especially with hyperaldosteronism and vasorenal hypertension, adrenal pathology, heart failure, lower T4 hormone levels, more low levels of HDL cholesterol, and a larger thickness of interventricular septum thickness; and patients receiving less calcium antagonists, centrally acting drugs, and aldosterone antagonists. Data are presented in **Table 4**.

**Table 5** presents the results of a regression analysis for the detection of predictors of resistance hypertension in patients receiving 3 or more antihypertensive drugs. The predictors for blood pressure reduction were male sex, left ventricular mass index, interventricular septum thickness, left ventricle posterior wall thickness, hypothyroidism, the presence of chronic kidney disease, CKD-EPI level, blood creatinine levels, the presence of heart failure, the presence of secondary hypertension, hyperaldosteronism, pituitary adenoma, and vasorenal hypertension.

Variables	Predictors of failure to reach the target BP	
Gender	$\beta = 0,119$	$P < 0,001$
Left ventricular mass index	$\beta = 0,139$	$P = 0,001$
Inter ventricular septum thickness	$\beta = 0,169$	$P = 0,002$
Left ventricle posterior wall thickness	$\beta = 0,147$	$P < 0,001$
Arterial hypertension	$\beta = 0,085$	$P = 0,009$
Arterial hypertension II	$\beta = 0,090$	$P = 0,005$
Arterial hypertension III	$\beta = 0,077$	$P = 0,018$
Secondary arterial hypertension	$\beta = 0,075$	$P = 0,020$
Vasorenal arterial hypertension	$\beta = 0,107$	$P = 0,001$
Hyperaldosteronism	$\beta = 0,064$	$P = 0,049$
Pituitary adenoma	$\beta = 0,068$	$P = 0,036$
Pathology of the thyroid gland	$\beta = 0,102$	$P = 0,002$
Hypothyroidism	$\beta = 0,069$	$P = 0,031$
Mixed goiter	$\beta = 0,072$	$P = 0,024$
Heart failure II	$\beta = 0,125$	$P < 0,001$
Chronic kidney disease	$\beta = 0,076$	$P = 0,018$
Creatinine	$\beta = 0,108$	$P = 0,028$
CKD-EPI	$\beta = 0,135$	$P = 0,025$
Office SBP mm Hg at hospitalization	$\beta = 0,368$	$P < 0,001$
Office DBP mm Hg at hospitalization	$\beta = 0,238$	$P < 0,001$
Calcium channel blockers	$\beta = -0,116$	$P = 0,001$
Central-acting agonists	$\beta = -0,146$	$P < 0,001$
Fixed combinations	$\beta = 0,098$	$P = 0,003$
Acetylsalicylic acid	$\beta = 0,103$	$P = 0,002$

**Table 5.**  
*Predictors of resistance hypertension in patients receiving 3 or more antihypertensive drugs (n = 1146).*



## 4. Discussion

Our data showed that in patients who received 3 or more antihypertensive drugs in 31%, the goal blood pressure (<140/90 mm Hg) was not reached, meaning it was true resistant hypertension. This is possible somewhat more than in other studies, but we have a specialized department, which is directed precisely by patients who failed to reach the target levels of blood pressure at the outpatient stage.

Among our patients with resistant arterial hypertension, 3 antihypertensive drugs were received by 51.4% of patients, 4 antihypertensive drugs were taken by 37.1% of patients, 5 antihypertensive drugs were taken by 9.1% of patients, and 6 antihypertensive drugs were taken by 2.4% of patients.

In our study ACE inhibitors were more often prescribed in 65.5% of patients, calcium antagonists in 69.9% of patients, and diuretics in 91.8% of patients. Beta-adrenergic blockers were administered to 75.5% of patients, receptor blockers to AT II to 33.5% of patients, and aldosterone receptor blockers to 12.8% of patients. Fixed combinations were taken by 71.9% of patients.

In our study patients who did not achieve targeted SBP (31%) had significantly higher blood pressure when inpatient. They had a significantly higher blood cortisol level ( $155.0 \pm 44.0$  vs.  $35.9 \pm 20.8$  ng/l) and the highest left ventricular mass index ( $147.5 \pm 3.46$  vs.  $135.3 \pm 1.74$  g/m<sup>2</sup>), and obesity (42.9 vs. 37.5%), kidney abnormality (2.7 vs. 0.8%), obliterative lower extremity atherosclerosis (2.0 vs. 0.2%), structural alterations in the adrenal gland (3.0 vs. 1.2%), nephropathy (1.3 vs. 0.2%), and more often heart failure (16.9 vs. 8.5%) were more common.

In our study, patients taking  $\geq 4$  drugs had significantly higher blood glucose levels—( $6.20 \pm 0.09$ ) mmol/l—than patients taking 3 drugs, ( $5.90 \pm 0.14$ ) mmol/l ( $p < 0.05$ ), and the highest level of renin plasma (( $218.30 \pm 15.73$ ) vs. ( $31.10 \pm 5.91$ ) ng/l ( $p < 0.05$ )). Renin-aldosterone ratio was almost twice as high ( $3.90 \pm 0.95$  vs.  $2.20 \pm 0.65$  U/d), although it did not differ significantly between patient groups.

Yook Chin Chia and Siew Mooi Ching studied the prevalence and predictors of resistance to hypertension in Southeast Asia [24]. The prevalence of resistant hypertension in the primary examination in their study was 8.8%. Their data also show that patients with chronic kidney disease were 2.9-fold more likely to develop resistant AH than in patients without CKD. This is consistent with the findings in other studies [25, 29]. In our study, CKD-EPI and CKD were predictors of resistance hypertension.

The authors explain this by the fact that in patients with CKD, there is increased sensitivity to salt, resulting in a delay in sodium and fluid, which leads to more complex control of blood pressure [24]. Patients in the Yook Chin Chia study were aged 66.9 years. In our study, patients were more younger,  $57.9 \pm 0.37$ . Resistant hypertension in Yook Chin Chia study was negatively related to age, which the authors explain with the effect of survival of patients who were treated compared with those patients who already had complications from uncontrolled hypertension. In our study, office SBP/DBP was worse in younger age patients.

Many studies have shown that most patients with hypertension need 2 or more drugs to achieve the target blood pressure [2, 30–34]. The average number of AH drugs used in their study was 2. They also showed poor monitoring of blood pressure among those taking only 2 drugs; even in those who received 3 drugs, the level of blood pressure control was less than 50%. However, in general, the use of diuretics in their study was low.

Holmqvist et al. studied the adherence to treatment in patients with resistance to hypertension, which controlled or did not control blood pressure and what factors contributed to nonadherence to treatment. 5846 patients received treatment with 3 or more AH drugs for 2 years [26]. Patients who achieved target blood pressure

levels were older in age and among them those with diabetes were fewer. Initially, patients had an adherence above 80%. During the first year of treatment, the adherence decreased by 11%, regardless of whether it was controlled or not controlled. The highest adherence was observed only in patients with diabetes mellitus and hypertension, in which the authors explain the structuring of the treatment of such a patient.

Resistant hypertension is associated with significant adverse effects, including an increased risk of cardiovascular events and death as well as a decrease in the quality of life [22, 24]. The exact mechanisms underlying the development of resistant hypertension remain unclear, although several mechanisms were proposed [8, 9, 35, 36]. An increase in fluid content and an increase in the level of aldosterone play a crucial role in the development of resistance hypertension, whereas enhanced activation of the sympathoadrenal system significantly contributes to refractory hypertension [14, 20, 34].

In conclusion, the predictors for blood pressure reduction were male sex, left ventricular mass index, interventricular septum thickness, left ventricle posterior wall thickness, the presence of chronic kidney disease, CKD-EPI level, blood creatinine levels, and the presence of heart failure.

## Disclosure


None.

## Author details

Yuriy Mykolayovych Sirenko, Oksana Leonidivna Rekovets and  
Olena Oleksandrivna Torbas\*  
FI “NSC” Institute of Cardiology named after M.D. Strazhesko NAMS of Ukraine,  
Kyiv, Ukraine

\*Address all correspondence to: [olenatorbas@gmail.com](mailto:olenatorbas@gmail.com)

## IntechOpen

© 2019 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution License (<http://creativecommons.org/licenses/by/3.0>), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 

## References

- [1] Hajjar I, Kotchen TA. Trends in prevalence, awareness, treatment, and control of hypertension in the United States, 1988-2000. *Journal of the American Medical Association*. 2003;**290**:199-206
- [2] Lloyd-Jones DM, Evans JC, Larson MG, O'Donnell CJ, Rocella EJ, Levy D. Differential control of systolic and diastolic blood pressure: Factors associated with lack of blood pressure control in the community. *Hypertension*. 2000;**36**:594-599
- [3] Chobanian AV, Bakris GL, Black HR, et al. The seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure: The JNC 7 report. *Journal of the American Medical Association*. 2003;**289**(19):2560-2572
- [4] Hwang AY, Dietrich E, Pepine CJ, Smith SM. Resistant hypertension: Mechanisms and treatment. *Current Hypertension Reports*. 2017;**19**:56. DOI: 10.1007/s11906-017-0754-x
- [5] Bangalore S, Fayyad R, Laskey R, et al. Prevalence, predictors, and outcomes in treatment-resistant hypertension in patients with coronary disease. *The American Journal of Medicine*. 2014;**127**(1):71-81.e71
- [6] Benjamin EJ, Blaha MJ, Chiuve SE, et al. Heart disease and stroke statistics—2017 update: A report from the American Heart Association. *Circulation*. 2017;**135**:e146-e603
- [7] Brandani L. Resistant hypertension: A therapeutic challenge. *Journal of Clinical Hypertension*. 2018;**20**:76-78
- [8] Roush GC, Holford TR, Guddati AK. Chlorthalidone compared with hydrochlorothiazide in reducing cardiovascular events: Systematic review and network meta-analyses. *Hypertension*. 2012;**59**(6):1110-1117
- [9] Sarafidis PA, Georgianos P, Bakris GL. Resistant hypertension—Its identification and epidemiology. *Nature Reviews Nephrology*. 2013;**9**(1):51-58
- [10] Williams B, Mancia G, Spiering W, et al. ESC/ESH guidelines for the management of arterial hypertension the task force for the management of arterial hypertension of the European Society of Cardiology (ESC) and the European Society of Hypertension (ESH). *European Heart Journal*. 2018;**00**:1-98. DOI: 10.1093/eurheartj/ehy339
- [11] Carris NW, Ghushchyan V, Libby AM, Smith SM. Health-related quality of life in persons with apparent treatment-resistant hypertension on at least four antihypertensives. *Journal of Human Hypertension*. 2016;**30**(3):191-196
- [12] Hall JE, do Carmo JM, da Silva AA, Wang Z, Hall ME. Obesity-induced hypertension: Interaction of neurohumoral and renal mechanisms. *Circulation Research*. 2015;**116**(6):991-1006
- [13] Hwang AY, Dave C, Smith SM. Trends in antihypertensive medication use among US patients with resistant hypertension, 2008 to 2014. *Hypertension*. 2016;**68**(6):1349-1354
- [14] Pimenta E, Gaddam KK, Oparil S, et al. Effects of dietary sodium reduction on blood pressure in subjects with resistant hypertension: Results from a randomized trial. *Hypertension*. 2009;**54**(3):475-481
- [15] Garg JP, Elliott WJ, Folker A, Izhar M, Black HR. Resistant hypertension revisited: A comparison of two university-based cohorts.

American Journal of Hypertension. 2005;**18**(5 Pt 1):619-626

[16] Gerritsen J, Dekker JM, TenVoorde BJ, et al. Impaired autonomic function is associated with increased mortality, especially in subjects with diabetes, hypertension, or a history of cardiovascular disease: The Hoorn study. *Diabetes Care*. 2001;**24**(10):1793-1798

[17] Gifford RW Jr, Tarazi RC. Resistant hypertension: Diagnosis and management. *Annals of Internal Medicine*. 1978;**88**(5):661-665

[18] Irvin MR, Booth JN 3rd, Shimbo D, et al. Apparent treatment-resistant hypertension and risk for stroke, coronary heart disease, and all-cause mortality. *Journal of the American Society of Hypertension*. 2014;**8**(6):405-413

[19] Le Jemtel TH, Richardson W, Samson R, Jaiswal A, Oparil S. Pathophysiology and potential non-pharmacologic treatments of obesity or kidney disease associated refractory hypertension. *Current Hypertension Reports*. 2017;**19**(2):18

[20] Taler SJ, Textor SC, Augustine JE. Resistant hypertension: Comparing hemodynamic management to specialist care. *Hypertension*. 2002;**39**(5):982-988

[21] Vlase HL, Panagopoulos G, Michelis MF. Effectiveness of furosemide in uncontrolled hypertension in the elderly: Role of renin profiling. *American Journal of Hypertension*. 2003;**16**(3):187-193

[22] Siddiqui M, Dudenbostel T, Calhoun DA. Resistant and refractory hypertension: Antihypertensive treatment resistance vs treatment failure. *The Canadian Journal of Cardiology*. 2016;**32**(5):603-606

[23] Hermida RC, Ayala DE, Smolensky MH, Fernandez JR, Mojon A,

Portaluppi F. Chronotherapy with conventional blood pressure medications improves management of hypertension and reduces cardiovascular and stroke risks. *Hypertension Research*. 2016;**39**(5):277-292

[24] Chia YC, Ching SM. Prevalence and predictors of resistant hypertension in a primary care setting: A cross-sectional study. *BMC Family Practice*. 2014;**15**:131. Available from: <http://www.biomedcentral.com/1471-2296/15/131>

[25] Feng W, Dell'Italia LJ, Sanders PW. Novel paradigms of salt and hypertension. *Journal of the American Society of Nephrology*. 2017;**28**(5):1362-1369

[26] Holmqvist L, Boström KB, Kahan T, Schiöler L, Qvarnström M, Wettermark B, et al. Drug adherence in treatment resistant and in controlled hypertension-results from the Swedish primary care cardiovascular database (SPCCD). *Pharmacoepidemiology and Drug Safety*. 2018;**27**(3):315-321. DOI: 10.1002/pds.4388

[27] Gorbas IM, Smirnova IP, Vakalyuk IP, et al. Epidemiolohichna sytuatsia arterialnoy hypertensii u silskiy populyatsii in Ukraine. *Liku Ukraine*. No. 7. 2013. pp. C88-C91

[28] Kvasha EA, Gorbas IM, Smirnova IP, Sribna IV. Arterialna hipertenzia: 35-letnia dinamika rasprostranionosti i effektivnosti kontrolya na populyatsionnom urovne sredi muzchin v. No. 3. 2016. pp. C18-C23

[29] Duprez DA. Aldosterone and the vasculature: Mechanisms mediating resistant hypertension. *Journal of Clinical Hypertension*. 2007;**9**(1 Suppl 1):13-18

[30] Ernst ME, Moser M. Use of diuretics in patients with hypertension. *The*



New England Journal of Medicine.  
2009;**361**(22):2153-2164

[31] Gaddam KK, Nishizaka MK, Pratt-Ubunama MN, et al. Characterization of resistant hypertension: Association between resistant hypertension, aldosterone, and persistent intravascular volume expansion. *Archives of Internal Medicine*. 2008;**168**(11):1159-1164

[32] Humphrey JD, Harrison DG, Figueroa CA, Lacolley P, Laurent S. Central artery stiffness in hypertension and aging: A problem with cause and consequence. *Circulation Research*. 2016;**118**(3):379-381

[33] Kumbhani DJ, Steg PG, Cannon CP, et al. Resistant hypertension: A frequent and ominous finding among hypertensive patients with atherothrombosis. *European Heart Journal*. 2013;**34**(16):1204-1214

[34] Mills KT, Bundy JD, Kelly TN, et al. Global disparities of hypertension prevalence and control: A systematic analysis of population-based studies from 90 countries. *Circulation*. 2016;**134**(6):441-450

[35] Rimoldi SF, Scherrer U, Messerli FH. Secondary arterial hypertension: When, who, and how to screen? *European Heart Journal*. 2014;**35**(19):1245-1254

[36] Zygmuntowicz M, Owczarek A, Elibol A, Olszanecka-Glinianowicz M, Chudek J. Blood pressure for optimal health- related quality of life in hypertensive patients. *Journal of Hypertension*. 2013;**31**(4):830-839